Related Experiment Video
Updated: Jul 12, 2026
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Analysis of somatostatin receptor subtype mRNA expression in human breast cancer
Abstract:
Somatostatin is a widely distributed inhibitory peptide with growth-inhibitory effects in several human tumours, including breast cancer, raising the possibility that it may have therapeutic potential. The effects of somatostatin are mediated via a family of cell-surface receptors that differ in their tissue distribution, pharmacological properties and intracellular response mediators, suggesting that they mediate different functions of the peptide. We have analysed the expression of somatostatin receptor subtype (SSTR1-5) mRNA in normal and malignant breast tissue. Receptor expression was analysed by reverse transcription-polymerase chain reaction (RT-PCR) using receptor subtype-specific primers and by in situ hybridization (ISH) with riboprobes synthesized by in vitro transcription of cloned PCR products. A total of 51 breast carcinomas, 36 samples of matched normal tissue, two axillary node metastases and eight normal/benign breast tissue samples were analysed. SSTR2 expression was ubiquitous in both normal and malignant breast tissue. Expression of SSTR5 was detected in approximately one-third of tumour and normal tissue, but fewer than 13% of all tissues expressed SSTR1, 3 and 4. These data suggest that SSTR2 gene expression is ubiquitous in breast cancer. Although this is unlikely to have diagnostic or prognostic significance, SSTR2-specific somatostatin analogues may have therapeutic potential in breast cancer.
Insights
Somatostatin receptor 2 (SSTR2) mRNA is widely present in both normal and malignant breast tissues. This ubiquitous SSTR2 expression suggests potential therapeutic applications for SSTR2-specific somatostatin analogues in breast cancer treatment.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Somatostatin is an inhibitory peptide with demonstrated growth-inhibitory effects on human tumors, including breast cancer.
- Somatostatin exerts its effects through a family of cell-surface receptors (SSTR1-5) with varying tissue distribution and functions.
- Understanding somatostatin receptor expression is crucial for exploring its therapeutic potential in breast cancer.
Purpose of the Study:
- To analyze the expression of somatostatin receptor subtypes (SSTR1-5) mRNA in normal and malignant breast tissues.
- To investigate the differential expression patterns of SSTR subtypes in breast cancer.
- To assess the potential diagnostic, prognostic, or therapeutic significance of SSTR expression in breast cancer.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) was employed to quantify SSTR1-5 mRNA expression using subtype-specific primers.
- In situ hybridization (ISH) was utilized with synthesized riboprobes to localize SSTR mRNA expression within tissue samples.
- Analysis included 51 breast carcinomas, 36 matched normal tissues, 2 axillary node metastases, and 8 normal/benign breast tissues.
Main Results:
- Somatostatin receptor 2 (SSTR2) mRNA expression was found to be ubiquitous in both normal and malignant breast tissues.
- SSTR5 mRNA expression was detected in approximately one-third of both tumor and normal tissue samples.
- SSTR1, SSTR3, and SSTR4 mRNA expression was detected in fewer than 13% of all analyzed tissues.
Conclusions:
- SSTR2 gene expression is ubiquitous in breast cancer, suggesting it is a common feature of the disease.
- While SSTR2 expression may lack diagnostic or prognostic value, its widespread presence indicates therapeutic potential.
- SSTR2-specific somatostatin analogues represent a promising therapeutic strategy for breast cancer treatment.
